Botox is well known for its cosmetic uses, but researchers have now found that it can also significantly improve people's quality of life if they suffer from another problem that increases with age, an overactive bladder (OAB).

Ipsen (Paris:IPN) today announced that the U.S. Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Reloxin® (botulinum toxin of type A) Biologics License Application (BLA) in aesthetic indications (glabellar lines) has been extended to April 13, 2009.

The American Academy of Cosmetic Surgery (AACS) announces the results of its 2007 Procedural Data and since 2002, the average age for patients receiving invasive cosmetic surgery has increased.

Botox and Botox Cosmetics safety reviews have linked this beauty procedure to respiratory failure and death, following treatment of a variety of conditions using a wide range of doses.